Ucb S A (UCBJF) 81.4300 $UCBJF Lannett (LCI) to Buy

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2015 at 8:27 AM

Ucb S A (UCBJF) 81.4300 $UCBJF

Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 57.14 (+0.52), JNJ: 92.93 (+0.21), CORT: 5.06 (+0.01)

Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), NVS: 96.55 (+0.28)

Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 295.24 (+1.64), PGNX: 7.34 (+0.22), RDY: 61.36 (+0.47)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Immunomedics Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws
Business Wire - Tue Jul 28, 2:35PM CDT
Levi & Korsinsky is investigating the Board of Directors of Immunomedics Inc. ("Immunomedics" or the "Company"

(NASDAQGM:IMMU) for possible violations of federal securities laws. The investigation concerns whether Immunomedics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 28, 2015, UCB SA, Immunomedics' collaboration partner, announced that their drug epratuzumab failed two Phase 3 studies. Upon the announcement of this news, the share price of Immunomedics stock plunged approximately $1.20, or 32%, in intraday trading from its closing price of $9.71 on July 27, 2015. To obtain additional information, go to:
IMMU: 2.22 (+0.01)

Week In Review: Livzon Leads $26 Million Funding Of Cynvenio
ChinaBio Today - at Seeking Alpha - Sun Jun 21, 4:57AM CDT
Deals and Financings Livzon Pharma (SZ: 000513 HK: 01513) of Zuhai, China, led a $25.5 million Series B funding of Cynvenio Biosystems, a Los Angeles area diagnostics company. Cynvenio is developing LiquidBiopsy, a technology that performs genomic...
JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), PFE: 32.97 (+0.35), WX: 42.90 (-0.10)

UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 225.64 (-3.15), BIOD: 0.67 (+0.03)

Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 225.64 (-3.15), IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35)

Dr. Reddy's (RDY) Earnings and Revenues Rise in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 9:00AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 49 cents, up 8.9% from the year-ago quarter.
SUPN: 20.20 (+0.75), RDY: 61.36 (+0.47)

Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 2.96 (+0.37), BIIB: 315.37 (+2.75), IMMU: 2.22 (+0.01)

UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 1:40PM CDT
UCB S.A. (UCBJF) will sell its established brands portfolio in India, to Dr. Reddy's Laboratories Ltd. to focus on core business.
CYTK: 7.31 (-0.08), LCI: 57.14 (+0.52), RDY: 61.36 (+0.47)

Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 315.37 (+2.75), ACT: 298.98 (-2.94), VRX: 225.64 (-3.15), PCYC: 261.25 (+1.70), OSIR: 19.32 (+0.52), ACOR: 33.07 (+0.14), HSP: 89.95 (-0.01), AGN: 295.24 (+1.64), MDVN: 95.48 (-0.65), ESRX: 84.49 (+0.59), SHPG: 223.00 (-2.43), ABBV: 59.35 (-0.23), SNY: 50.23 (+0.46), ARNA: 2.86 (+0.15), REGN: 533.30 (+2.08), ABT: 43.41 (+0.29), ENDP: 74.80 (-0.43), AKRX: 38.38 (+0.33), PFE: 32.97 (+0.35), INCY: 131.01 (+6.51), SLXP: 172.96 (+0.15), AMGN: 153.21 (+0.07), MYL: 48.65 (+0.85), LLY: 81.80 (+0.96), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), ALKS: 70.95 (+1.28), MNKD: 3.70 (-0.05), OREX: 2.44 (-0.44), NVO: 56.95 (+0.37), ISIS: 54.08 (+1.07), GERN: 3.53 (+0.15), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), PBYI: 103.28 (+6.59), NVS: 96.55 (+0.28)

Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 315.37 (+2.75), ACT: 298.98 (-2.94), VRX: 225.64 (-3.15), PCYC: 261.25 (+1.70), OSIR: 19.32 (+0.52), ACOR: 33.07 (+0.14), HSP: 89.95 (-0.01), AGN: 295.24 (+1.64), MDVN: 95.48 (-0.65), ESRX: 84.49 (+0.59), SHPG: 223.00 (-2.43), ABBV: 59.35 (-0.23), SNY: 50.23 (+0.46), ARNA: 2.86 (+0.15), REGN: 533.30 (+2.08), ABT: 43.41 (+0.29), ENDP: 74.80 (-0.43), AKRX: 38.38 (+0.33), PFE: 32.97 (+0.35), INCY: 131.01 (+6.51), SLXP: 172.96 (+0.15), AMGN: 153.21 (+0.07), MYL: 48.65 (+0.85), LLY: 81.80 (+0.96), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), ALKS: 70.95 (+1.28), MNKD: 3.70 (-0.05), OREX: 2.44 (-0.44), NVO: 56.95 (+0.37), ISIS: 54.08 (+1.07), GERN: 3.53 (+0.15), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), PBYI: 103.28 (+6.59), NVS: 96.55 (+0.28)

UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 57.14 (+0.52), SCMP: 25.30 (+0.49), BIOD: 0.67 (+0.03)

Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics
ChinaBio Today - at Seeking Alpha - Sun Feb 08, 3:46AM CST
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE: WX ), led a $15 million Series B financing in Claritas Genomics (see story ). Claritas is a Boston-based lab that...
MRK: 52.09 (-0.63), WX: 42.90 (-0.10)

UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 12.94 (+0.47), AMGN: 153.21 (+0.07), BIOD: 0.67 (+0.03)

Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), BIOD: 0.67 (+0.03)

UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 1:10PM CST
UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization of Parkinson's disease related therapies.
LCI: 57.14 (+0.52), ENDP: 74.80 (-0.43), BIOD: 0.67 (+0.03)

UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 223.00 (-2.43), AMGN: 153.21 (+0.07), NVS: 96.55 (+0.28)

Immunomedics: Under-Followed Company With Robust Pipeline And Huge Growth Potential
Bridging the Gap - at Seeking Alpha - Fri Dec 26, 4:17PM CST

IMMU: 2.22 (+0.01)

UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 57.14 (+0.52), VRX: 225.64 (-3.15), SCMP: 25.30 (+0.49)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...